According to a media report on the MarketWatch web site, a company called OncBioMune is to initiate Phase II clinical trials of a new type of prostate cancer vaccine (ProscaVax). … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: cancer, localized, Phase II, prostate, trial, vaccine | 2 Comments »
In June this year, SophirisBio (a West Coast biotech company) initiated a Phase IIb clinical trial of its investigational drug PRX302 (also known as topsalysin) in the treatment of low- and intermediate-risk, localized prostate cancer. … READ MORE …
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: Phase II, PRX302, topsalysin, trial | 7 Comments »
Data from a small, distinctly esoteric, Phase II clinical trial of a form of prostate cancer suicide gene therapy along with radiation therapy have suggested that such treatment may be able to stop the development of some early stage forms of prostate cancer (but such data need to be interpreted with great care). … READ MORE …
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: gene, intermediate, Phase II, radiation, risk, therapy | 5 Comments »
Now here’s an embarrassing admission for a drug development company to have to make … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: endpoint, NX-1207, outcome, Phase II, trial | 9 Comments »
According to a company media release, Aeterna Zentaris has initiated the Phase II component of the Phase I/II trial of AEZS 108 in the treatment of men with castration- and taxane-resistant prostate cancer. … READ MORE …
Filed under: Drugs in development, Management | Tagged: AEZS-108, mCRPC, Phase II, trial | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 